V
31.90
-1.30 (-3.92%)
| 前收盘价格 | 33.20 |
| 收盘价格 | 33.07 |
| 成交量 | 1,568,268 |
| 平均成交量 (3个月) | 1,641,781 |
| 市值 | 3,044,600,064 |
| 价格/销量 (P/S) | 38.52 |
| 股市价格/股市净资产 (P/B) | 10.20 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2025 |
| 营业利益率 (TTM) | -130,369.45% |
| 稀释每股收益 (EPS TTM) | -3.35 |
| 总债务/股东权益 (D/E MRQ) | 3.82% |
| 流动比率 (MRQ) | 19.49 |
| 营业现金流 (OCF TTM) | -279.75 M |
| 杠杆自由现金流 (LFCF TTM) | -171.41 M |
| 资产报酬率 (ROA TTM) | -32.62% |
| 股东权益报酬率 (ROE TTM) | -51.95% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Viridian Therapeutics, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
1.1
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.13 |
|
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.16% |
| 机构持股比例 | 114.61% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Vr Adviser, Llc | 30 Sep 2025 | 3,882,709 |
| Fairmount Funds Management Llc | 30 Sep 2025 | 3,459,913 |
| Maverick Capital Ltd | 30 Sep 2025 | 2,212,701 |
| Eversept Partners, Lp | 30 Sep 2025 | 1,924,306 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 50.00 (UBS, 56.74%) | 购买 |
| 中 | 43.50 (36.36%) | |
| 低 | 29.00 (Wells Fargo, -9.09%) | 保留 |
| 平均值 | 42.17 (32.19%) | |
| 总计 | 5 购买, 1 保留 | |
| 平均价格@调整类型 | 31.34 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Needham | 04 Feb 2026 | 42.00 (31.66%) | 购买 | 33.53 |
| 23 Dec 2025 | 42.00 (31.66%) | 购买 | 32.11 | |
| Wells Fargo | 03 Feb 2026 | 29.00 (-9.09%) | 保留 | 33.53 |
| Truist Securities | 08 Jan 2026 | 40.00 (25.39%) | 购买 | 30.33 |
| 24 Nov 2025 | 41.00 (28.53%) | 购买 | 32.03 | |
| UBS | 07 Jan 2026 | 50.00 (56.74%) | 购买 | 30.57 |
| Wedbush | 10 Dec 2025 | 47.00 (47.34%) | 购买 | 32.60 |
| RBC Capital | 06 Nov 2025 | 45.00 (41.07%) | 购买 | 27.50 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合